GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0090312 | Oral cavity | OSCC | positive regulation of protein deacetylation | 20/7305 | 25/18723 | 3.47e-05 | 3.11e-04 | 20 |
GO:00421582 | Oral cavity | OSCC | lipoprotein biosynthetic process | 57/7305 | 96/18723 | 4.17e-05 | 3.61e-04 | 57 |
GO:000189216 | Oral cavity | OSCC | embryonic placenta development | 50/7305 | 82/18723 | 4.58e-05 | 3.90e-04 | 50 |
GO:0006270 | Oral cavity | OSCC | DNA replication initiation | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
GO:190370618 | Oral cavity | OSCC | regulation of hemopoiesis | 180/7305 | 367/18723 | 5.16e-05 | 4.30e-04 | 180 |
GO:00062753 | Oral cavity | OSCC | regulation of DNA replication | 62/7305 | 107/18723 | 5.49e-05 | 4.54e-04 | 62 |
GO:00094164 | Oral cavity | OSCC | response to light stimulus | 159/7305 | 320/18723 | 5.98e-05 | 4.92e-04 | 159 |
GO:19020991 | Oral cavity | OSCC | regulation of metaphase/anaphase transition of cell cycle | 40/7305 | 63/18723 | 7.19e-05 | 5.67e-04 | 40 |
GO:00481446 | Oral cavity | OSCC | fibroblast proliferation | 49/7305 | 81/18723 | 7.27e-05 | 5.72e-04 | 49 |
GO:00450502 | Oral cavity | OSCC | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 10/7305 | 10/18723 | 8.14e-05 | 6.26e-04 | 10 |
GO:00066651 | Oral cavity | OSCC | sphingolipid metabolic process | 84/7305 | 155/18723 | 8.64e-05 | 6.61e-04 | 84 |
GO:1902749 | Oral cavity | OSCC | regulation of cell cycle G2/M phase transition | 59/7305 | 102/18723 | 8.81e-05 | 6.72e-04 | 59 |
GO:19019895 | Oral cavity | OSCC | positive regulation of cell cycle phase transition | 65/7305 | 115/18723 | 1.03e-04 | 7.69e-04 | 65 |
GO:00075698 | Oral cavity | OSCC | cell aging | 73/7305 | 132/18723 | 1.05e-04 | 7.75e-04 | 73 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:00002889 | Oral cavity | OSCC | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
GO:00103326 | Oral cavity | OSCC | response to gamma radiation | 36/7305 | 56/18723 | 1.12e-04 | 8.24e-04 | 36 |
GO:00481457 | Oral cavity | OSCC | regulation of fibroblast proliferation | 48/7305 | 80/18723 | 1.14e-04 | 8.35e-04 | 48 |
GO:0010972 | Oral cavity | OSCC | negative regulation of G2/M transition of mitotic cell cycle | 38/7305 | 60/18723 | 1.17e-04 | 8.46e-04 | 38 |
GO:1902750 | Oral cavity | OSCC | negative regulation of cell cycle G2/M phase transition | 39/7305 | 62/18723 | 1.19e-04 | 8.54e-04 | 39 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0481041 | Liver | HCC | Regulation of actin cytoskeleton | 134/4020 | 229/8465 | 4.48e-04 | 1.94e-03 | 1.08e-03 | 134 |
hsa0502032 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C6 | SNV | Missense_Mutation | | c.201N>C | p.Lys67Asn | p.K67N | P13671 | protein_coding | tolerated(0.09) | possibly_damaging(0.717) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
C6 | SNV | Missense_Mutation | | c.1672G>A | p.Asp558Asn | p.D558N | P13671 | protein_coding | tolerated(0.09) | benign(0.29) | TCGA-A8-A09B-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
C6 | SNV | Missense_Mutation | | c.1375N>G | p.Lys459Glu | p.K459E | P13671 | protein_coding | deleterious(0) | probably_damaging(0.934) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs369381506 | c.1067N>A | p.Arg356Gln | p.R356Q | P13671 | protein_coding | tolerated(0.17) | benign(0.098) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | rs763860114 | c.2522G>A | p.Arg841His | p.R841H | P13671 | protein_coding | tolerated(0.19) | benign(0.35) | TCGA-C8-A12Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | SNV | Missense_Mutation | | c.311N>T | p.Arg104Ile | p.R104I | P13671 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
C6 | SNV | Missense_Mutation | novel | c.1177N>A | p.Glu393Lys | p.E393K | P13671 | protein_coding | tolerated(0.24) | benign(0.169) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828_829insG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C6 | deletion | Frame_Shift_Del | rs372345940 | c.828delN | p.Ser277AlafsTer43 | p.S277Afs*43 | P13671 | protein_coding | | | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C6 | insertion | Frame_Shift_Ins | rs762335076 | c.828dupG | p.Ser277GlufsTer15 | p.S277Efs*15 | P13671 | protein_coding | | | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |